drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06595 | DB11560 | 1,491 | 1,678 | [
"DDInter1214",
"DDInter1038"
] | Midostaurin | Lesinurad | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia. Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout. | Moderate | 1 | [
[
[
1491,
24,
1678
]
],
[
[
1491,
63,
1374
],
[
1374,
24,
1678
]
],
[
[
1491,
25,
877
],
[
877,
63,
1678
]
],
[
[
1491,
24,
1040
],
[
1040... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Lesinurad |
DB00902 | DB06702 | 104 | 573 | [
"DDInter1168",
"DDInter731"
] | Methdilazine | Fesoterodine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
104,
24,
573
]
],
[
[
104,
24,
211
],
[
211,
1,
573
]
],
[
[
104,
63,
494
],
[
494,
1,
573
]
],
[
[
104,
63,
100
],
[
100,
24,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Methdilazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Methdilazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Methdilazine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Disopyramide (Compound) and Disopyramide (Compound) resembles Fesoterodine (Compound) |
DB00552 | DB08895 | 1,238 | 976 | [
"DDInter1425",
"DDInter1825"
] | Pentostatin | Tofacitinib | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Major | 2 | [
[
[
1238,
25,
976
]
],
[
[
1238,
24,
200
],
[
200,
63,
976
]
],
[
[
1238,
24,
1430
],
[
1430,
24,
976
]
],
[
[
1238,
25,
1011
],
[
1011,
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"C... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Pentostatin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Tofacitinib
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Tofacitinib
Pentostatin may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Tofacitinib
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may lead to a major life threatening interaction when taken with Tofacitinib
Pentostatin (Compound) resembles Trifluridine (Compound) and Trifluridine may lead to a major life threatening interaction when taken with Tofacitinib
Pentostatin (Compound) resembles Floxuridine (Compound) and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may lead to a major life threatening interaction when taken with Tofacitinib |
DB00334 | DB11986 | 867 | 484 | [
"DDInter1326",
"DDInter648"
] | Olanzapine | Entrectinib | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
867,
24,
484
]
],
[
[
867,
23,
112
],
[
112,
23,
484
]
],
[
[
867,
24,
222
],
[
222,
23,
484
]
],
[
[
867,
24,
774
],
[
774,
24,... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Olanzapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Entrectinib |
DB00451 | DB01377 | 542 | 1,283 | [
"DDInter1064",
"DDInter1119"
] | Levothyroxine | Magnesium oxide | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or ), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.[F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
542,
24,
1283
]
],
[
[
542,
62,
461
],
[
461,
23,
1283
]
],
[
[
542,
63,
1252
],
[
1252,
23,
1283
]
],
[
[
542,
24,
1482
],
[
1482,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
... | Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Labetalol and Labetalol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide |
DB00446 | DB08899 | 597 | 129 | [
"DDInter351",
"DDInter649"
] | Chloramphenicol | Enzalutamide | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
597,
24,
129
]
],
[
[
597,
6,
8374
],
[
8374,
45,
129
]
],
[
[
597,
21,
28703
],
[
28703,
60,
129
]
],
[
[
597,
23,
271
],
[
271,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Chloramphenicol (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB00327 | DB00574 | 421 | 121 | [
"DDInter890",
"DDInter717"
] | Hydromorphone | Fenfluramine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential). The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984. | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome and Lennox-Gastaut syndrome through the restricted FINTEPLA REMS program. It is currently sold under the name FINTEPLA® by Zogenix INC. | Moderate | 1 | [
[
[
421,
24,
121
]
],
[
[
421,
35,
173
],
[
173,
62,
121
]
],
[
[
421,
24,
1347
],
[
1347,
63,
121
]
],
[
[
421,
1,
828
],
[
828,
24... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when... | Hydromorphone (Compound) resembles Naloxone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone and Naloxone may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Hydromorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Hydromorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Hydromorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Fenfluramine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Fenfluramine
Hydromorphone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Fenfluramine |
DB00472 | DB00731 | 758 | 1,144 | [
"DDInter758",
"DDInter1269"
] | Fluoxetine | Nateglinide | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound. | Moderate | 1 | [
[
[
758,
24,
1144
]
],
[
[
758,
6,
6943
],
[
6943,
45,
1144
]
],
[
[
758,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
758,
25,
121
],
[
121,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"ORM1"
],
[
"ORM1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluoxetine (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Nateglinide (Compound)
Fluoxetine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Fluoxetine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fluoxetine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fluoxetine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide |
DB00653 | DB11921 | 544 | 1,019 | [
"DDInter1120",
"DDInter492"
] | Magnesium sulfate | Deflazacort | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
544,
24,
1019
]
],
[
[
544,
63,
355
],
[
355,
24,
1019
]
],
[
[
544,
24,
286
],
[
286,
24,
1019
]
],
[
[
544,
24,
646
],
[
646,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Cinoxacin and Cinoxacin may lead to a major life threatening interaction when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may lead to a major life threatening interaction when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort |
DB00701 | DB12332 | 1,091 | 1,619 | [
"DDInter90",
"DDInter1626"
] | Amprenavir | Rucaparib | Amprenavir is a protease inhibitor used to treat HIV infection. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1091,
24,
1619
]
],
[
[
1091,
23,
222
],
[
222,
23,
1619
]
],
[
[
1091,
25,
112
],
[
112,
23,
1619
]
],
[
[
1091,
24,
309
],
[
309,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Amprenavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Amprenavir may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amprenavir may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amprenavir may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amprenavir may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB00927 | DB01165 | 1,559 | 1,539 | [
"DDInter712",
"DDInter1325"
] | Famotidine | Ofloxacin | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
1559,
24,
1539
]
],
[
[
1559,
62,
1467
],
[
1467,
1,
1539
]
],
[
[
1559,
63,
1176
],
[
1176,
1,
1539
]
],
[
[
1559,
24,
945
],
[
945,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Ofloxacin (Compound)
Famotidine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Ofloxacin (Compound)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin
Famotidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin |
DB00619 | DB04574 | 1,419 | 177 | [
"DDInter909",
"DDInter684"
] | Imatinib | Estrone sulfate (topical) | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Moderate | 1 | [
[
[
1419,
24,
177
]
],
[
[
1419,
63,
380
],
[
380,
1,
177
]
],
[
[
1419,
24,
35
],
[
35,
1,
177
]
],
[
[
1419,
6,
10715
],
[
10715,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estrone sulfate (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Estrone sulfate (Compound)
Imatinib (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Estrone sulfate (Compound)
Imatinib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Estrone sulfate (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Imatinib may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Estrone sulfate |
DB00176 | DB11837 | 529 | 1,297 | [
"DDInter770",
"DDInter1351"
] | Fluvoxamine | Osilodrostat | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Moderate | 1 | [
[
[
529,
24,
1297
]
],
[
[
529,
23,
1135
],
[
1135,
23,
1297
]
],
[
[
529,
23,
466
],
[
466,
62,
1297
]
],
[
[
529,
25,
222
],
[
222,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Fluvoxamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Fluvoxamine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Osilodrostat
Fluvoxamine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Osilodrostat |
DB00252 | DB00290 | 362 | 329 | [
"DDInter1460",
"DDInter219"
] | Phenytoin | Bleomycin | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Moderate | 1 | [
[
[
362,
24,
329
]
],
[
[
362,
21,
28769
],
[
28769,
60,
329
]
],
[
[
362,
63,
58
],
[
58,
24,
329
]
],
[
[
362,
24,
372
],
[
372,
6... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effe... | Phenytoin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Bleomycin (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Phenytoin (Compound) resembles Fosphenytoin (Compound) and Fos
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Phenytoin may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Bleomycin
Phenytoin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Bleomycin
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bleomycin |
DB01234 | DB09045 | 1,220 | 52 | [
"DDInter513",
"DDInter607"
] | Dexamethasone | Dulaglutide | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations. | Moderate | 1 | [
[
[
1220,
24,
52
]
],
[
[
1220,
40,
1103
],
[
1103,
23,
52
]
],
[
[
1220,
24,
170
],
[
170,
23,
52
]
],
[
[
1220,
63,
609
],
[
609,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Dexamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Dexamethasone may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Dexamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Dexamethasone may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide |
DB00586 | DB09268 | 1,512 | 1,662 | [
"DDInter537",
"DDInter1464"
] | Diclofenac | Picosulfuric acid | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
1512,
24,
1662
]
],
[
[
1512,
23,
16
],
[
16,
23,
1662
]
],
[
[
1512,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
1512,
24,
1619
],
[
1619,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
... | Diclofenac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Diclofenac may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Diclofenac may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Ceftriaxone and Ceftriaxone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid |
DB00374 | DB09237 | 1,061 | 1,586 | [
"DDInter1852",
"DDInter1045"
] | Treprostinil | Levamlodipine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019. | Moderate | 1 | [
[
[
1061,
24,
1586
]
],
[
[
1061,
24,
578
],
[
578,
23,
1586
]
],
[
[
1061,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
1061,
24,
549
],
[
549,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Treprostinil may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Treprostinil may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Levamlodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine |
DB08899 | DB15328 | 129 | 829 | [
"DDInter649",
"DDInter1896"
] | Enzalutamide | Ubrogepant | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development.[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors. Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. Ubrogepant was approved by Health Canada on November 10, 2022. Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages. They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease. The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition. | Major | 2 | [
[
[
129,
25,
829
]
],
[
[
129,
25,
1476
],
[
1476,
24,
829
]
],
[
[
129,
24,
1468
],
[
1468,
24,
829
]
],
[
[
129,
64,
578
],
[
578,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ubrogepant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{... | Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enzalutamide may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enzalutamide (Compound) resembles Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ubrogepant
Enzalutamide may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Ubrogepant
Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant |
DB00018 | DB09472 | 199 | 1,383 | [
"DDInter945",
"DDInter1693"
] | Interferon alfa-n3 | Sodium sulfate | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions. | Moderate | 1 | [
[
[
199,
24,
1383
]
],
[
[
199,
24,
1031
],
[
1031,
24,
1383
]
],
[
[
199,
25,
593
],
[
593,
24,
1383
]
],
[
[
199,
24,
1031
],
[
1031,
... | [
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophy... | Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Oxamniquine and Oxamniquine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate |
DB01225 | DB06441 | 500 | 936 | [
"DDInter645",
"DDInter283"
] | Enoxaparin | Cangrelor | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313] | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application. | Major | 2 | [
[
[
500,
25,
936
]
],
[
[
500,
23,
1631
],
[
1631,
62,
936
]
],
[
[
500,
64,
97
],
[
97,
24,
936
]
],
[
[
500,
63,
383
],
[
383,
24,... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Enoxaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Enoxaparin may lead to a major life threatening interaction when taken with Oxaprozin and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Enoxaparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Ginseng and Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Enoxaparin may lead to a major life threatening interaction when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Cangrelor
Enoxaparin may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may lead to a major life threatening interaction when taken with Cangrelor
Enoxaparin may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Cangrelor |
DB00470 | DB01320 | 530 | 651 | [
"DDInter601",
"DDInter783"
] | Dronabinol | Fosphenytoin | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Moderate | 1 | [
[
[
530,
24,
651
]
],
[
[
530,
23,
307
],
[
307,
1,
651
]
],
[
[
530,
63,
362
],
[
362,
1,
651
]
],
[
[
530,
6,
6017
],
[
6017,
45,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dronabinol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Dronabinol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Dronabinol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Dronabinol (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Fosphenytoin (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Dronabinol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin |
DB00364 | DB00612 | 417 | 1,121 | [
"DDInter1717",
"DDInter216"
] | Sucralfate | Bisoprolol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. | Minor | 0 | [
[
[
417,
23,
1121
]
],
[
[
417,
23,
819
],
[
819,
40,
1121
]
],
[
[
417,
62,
88
],
[
88,
40,
1121
]
],
[
[
417,
21,
28882
],
[
28882,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bisoprolol"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol (Compound) resembles Bisoprolol (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Bisoprolol (Compound)
Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Bisoprolol (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a minor interaction that can limit clinical effects when taken with Bisoprolol
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Bisoprolol
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Bisoprolol
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol |
DB06204 | DB11817 | 768 | 1,259 | [
"DDInter1746",
"DDInter165"
] | Tapentadol | Baricitinib | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022. | Moderate | 1 | [
[
[
768,
24,
1259
]
],
[
[
768,
24,
407
],
[
407,
24,
1259
]
],
[
[
768,
64,
475
],
[
475,
24,
1259
]
],
[
[
768,
64,
1053
],
[
1053,
... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Tapentadol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Tapentadol may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Baricitinib
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may lead to a major life threatening interaction when taken with Baricitinib
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Tapentadol may lead to a major life threatening interaction when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Tapentadol may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib |
DB06616 | DB11828 | 594 | 1,406 | [
"DDInter224",
"DDInter1281"
] | Bosutinib | Neratinib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
594,
24,
1406
]
],
[
[
594,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
594,
24,
1475
],
[
1475,
24,
1406
]
],
[
[
594,
63,
1117
],
[
1117,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunom... | Bosutinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosutinib may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosutinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
Bosutinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Bosutinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may lead to a major life threatening interaction when taken with Neratinib |
DB00342 | DB00529 | 1,181 | 789 | [
"DDInter1770",
"DDInter779"
] | Terfenadine | Foscarnet | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Moderate | 1 | [
[
[
1181,
24,
789
]
],
[
[
1181,
23,
112
],
[
112,
62,
789
]
],
[
[
1181,
24,
1494
],
[
1494,
24,
789
]
],
[
[
1181,
24,
770
],
[
770,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Foscarnet
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Terfenadine may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Terfenadine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Terfenadine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Terfenadine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Foscarnet
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Foscarnet |
DB00400 | DB09073 | 353 | 951 | [
"DDInter843",
"DDInter1379"
] | Griseofulvin | Palbociclib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Moderate | 1 | [
[
[
353,
24,
951
]
],
[
[
353,
24,
907
],
[
907,
62,
951
]
],
[
[
353,
23,
271
],
[
271,
23,
951
]
],
[
[
353,
24,
479
],
[
479,
23,... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Griseofulvin may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may lead to a major life threatening interaction when taken with Palbociclib |
DB00682 | DB15233 | 126 | 1,650 | [
"DDInter1951",
"DDInter142"
] | Warfarin | Avapritinib | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020. | Major | 2 | [
[
[
126,
25,
1650
]
],
[
[
126,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
126,
63,
58
],
[
58,
24,
1650
]
],
[
[
126,
23,
918
],
[
918,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Warfarin may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Avapritinib
Warfarin may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Avapritinib
Warfarin may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Avapritinib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Avapritinib
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Avapritinib |
DB00586 | DB01021 | 1,512 | 674 | [
"DDInter537",
"DDInter1861"
] | Diclofenac | Trichlormethiazide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
1512,
24,
674
]
],
[
[
1512,
63,
1014
],
[
1014,
40,
674
]
],
[
[
1512,
24,
178
],
[
178,
1,
674
]
],
[
[
1512,
24,
359
],
[
359,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Trichlormethiazide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Trichlormethiazide (Compound)
Diclofenac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Diclofenac may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Diclofenac may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide |
DB01234 | DB08882 | 1,220 | 1,281 | [
"DDInter513",
"DDInter1070"
] | Dexamethasone | Linagliptin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011. | Moderate | 1 | [
[
[
1220,
24,
1281
]
],
[
[
1220,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
1220,
21,
30552
],
[
305... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Dexamethasone (Compound) causes Diabetic (Side Effect) and Diabetic (Side Effect) is caused by Linagliptin (Compound)
Dexamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Linagliptin
Dexamethasone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Dexamethasone may lead to a major life threatening interaction when taken with Lumateperone and Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Dexamethasone may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin |
DB00261 | DB08899 | 702 | 129 | [
"DDInter93",
"DDInter649"
] | Anagrelide | Enzalutamide | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Major | 2 | [
[
[
702,
25,
129
]
],
[
[
702,
25,
918
],
[
918,
1,
129
]
],
[
[
702,
21,
28703
],
[
28703,
60,
129
]
],
[
[
702,
23,
1247
],
[
1247,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
... | Anagrelide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Anagrelide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Anagrelide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB06402 | DB11110 | 1,079 | 603 | [
"DDInter1756",
"DDInter1115"
] | Telavancin | Magnesium citrate | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
1079,
24,
603
]
],
[
[
1079,
64,
57
],
[
57,
24,
603
]
],
[
[
1079,
24,
1616
],
[
1616,
24,
603
]
],
[
[
1079,
63,
1151
],
[
1151,
... | [
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Telavancin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate |
DB00280 | DB12500 | 494 | 283 | [
"DDInter575",
"DDInter714"
] | Disopyramide | Fedratinib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
494,
24,
283
]
],
[
[
494,
25,
351
],
[
351,
23,
283
]
],
[
[
494,
24,
1419
],
[
1419,
24,
283
]
],
[
[
494,
40,
211
],
[
211,
2... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Riboci... | Disopyramide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Disopyramide (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Disopyramide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Disopyramide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Disopyramide (Compound) resembles Fesoterodine (Compound) and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Disopyramide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib |
DB00445 | DB12500 | 322 | 283 | [
"DDInter655",
"DDInter714"
] | Epirubicin | Fedratinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
322,
24,
283
]
],
[
[
322,
25,
351
],
[
351,
23,
283
]
],
[
[
322,
24,
1339
],
[
1339,
62,
283
]
],
[
[
322,
24,
479
],
[
479,
2... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib... | Epirubicin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotralstat may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib and Pralsetinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Epirubicin may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Epirubicin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Epirubicin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib |
DB00773 | DB01206 | 896 | 37 | [
"DDInter702",
"DDInter1086"
] | Etoposide | Lomustine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
896,
24,
37
]
],
[
[
896,
5,
11613
],
[
11613,
44,
37
]
],
[
[
896,
6,
8374
],
[
8374,
45,
37
]
],
[
[
896,
21,
28722
],
[
28722,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Etoposide",
"{u} (Compound) treats {v} (Disease)",
"brain cancer"
],
[
"brain cancer",
"{u} (Disease) is treated b... | Etoposide (Compound) treats brain cancer (Disease) and brain cancer (Disease) is treated by Lomustine (Compound)
Etoposide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound)
Etoposide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lomustine
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Etoposide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Etoposide may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine |
DB08880 | DB09331 | 1,510 | 745 | [
"DDInter1771",
"DDInter478"
] | Teriflunomide | Daratumumab | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296] | Major | 2 | [
[
[
1510,
25,
745
]
],
[
[
1510,
64,
139
],
[
139,
24,
745
]
],
[
[
1510,
63,
597
],
[
597,
24,
745
]
],
[
[
1510,
25,
287
],
[
287,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
... | Teriflunomide may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Teriflunomide may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Teriflunomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Daratumumab
Teriflunomide may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Daratumumab
Teriflunomide may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Daratumumab |
DB00912 | DB06016 | 473 | 1,508 | [
"DDInter1581",
"DDInter300"
] | Repaglinide | Cariprazine | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] | Moderate | 1 | [
[
[
473,
24,
1508
]
],
[
[
473,
24,
1593
],
[
1593,
63,
1508
]
],
[
[
473,
63,
600
],
[
600,
24,
1508
]
],
[
[
473,
24,
1021
],
[
1021,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine |
DB00029 | DB04865 | 25 | 4 | [
"DDInter99",
"DDInter1335"
] | Anistreplase | Omacetaxine mepesuccinate | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Major | 2 | [
[
[
25,
25,
4
]
],
[
[
25,
24,
738
],
[
738,
63,
4
]
],
[
[
25,
25,
39
],
[
39,
63,
4
]
],
[
[
25,
25,
1213
],
[
1213,
24,
4
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Anistreplase may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Anistreplase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Anistreplase may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Anistreplase may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Anistreplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate |
DB01229 | DB04865 | 973 | 4 | [
"DDInter1377",
"DDInter1335"
] | Paclitaxel | Omacetaxine mepesuccinate | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Moderate | 1 | [
[
[
973,
24,
4
]
],
[
[
973,
7,
13042
],
[
13042,
46,
4
]
],
[
[
973,
18,
10351
],
[
10351,
46,
4
]
],
[
[
973,
18,
10488
],
[
10488,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Paclitaxel",
"{u} (Compound) upregulates {v} (Gene)",
"HIST1H2BK"
],
[
"HIST1H2BK",
"{u} (Gene) i... | Paclitaxel (Compound) upregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) downregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) downregulates B4GAT1 (Gene) and B4GAT1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) upregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) binds TUBB (Gene) and TUBB (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) binds TUBB6 (Gene) and Paclitaxel (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate |
DB08826 | DB08870 | 1,292 | 850 | [
"DDInter489",
"DDInter228"
] | Deferiprone | Brentuximab vedotin | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Major | 2 | [
[
[
1292,
25,
850
]
],
[
[
1292,
64,
611
],
[
611,
24,
850
]
],
[
[
1292,
25,
1583
],
[
1583,
63,
850
]
],
[
[
1292,
63,
1512
],
[
1512,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",... | Deferiprone may lead to a major life threatening interaction when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin |
DB00697 | DB11901 | 876 | 913 | [
"DDInter1821",
"DDInter107"
] | Tizanidine | Apalutamide | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
876,
24,
913
]
],
[
[
876,
23,
112
],
[
112,
23,
913
]
],
[
[
876,
63,
600
],
[
600,
24,
913
]
],
[
[
876,
24,
485
],
[
485,
24,... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Tizanidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Tizanidine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Tizanidine may lead to a major life threatening interaction when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Tizanidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Tizanidine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Apalutamide
Tizanidine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Apalutamide |
DB00349 | DB01246 | 902 | 820 | [
"DDInter401",
"DDInter45"
] | Clobazam | Alimemazine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.[A256963,A256868] This is likely because of clobazam's higher affinity to the α<sub>2</sub> subunit of the GABA<sub>A</sub> receptor, which mediates anxiolytic effects, than the α<sub>1</sub> subunit, which mediates sedative effect. Additionally, clobazam is believed | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
902,
24,
820
]
],
[
[
902,
24,
104
],
[
104,
40,
820
]
],
[
[
902,
40,
1335
],
[
1335,
24,
820
]
],
[
[
902,
24,
401
],
[
401,
2... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Clobazam (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Alimemazine (Compound)
Clobazam (Compound) resembles Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Alimemazine (Compound)
Clobazam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Clobazam (Compound) causes Respiratory depression (Side Effect) and Respiratory depression (Side Effect) is caused by Alimemazine (Compound)
Clobazam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Alimemazine
Clobazam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine |
DB00060 | DB12001 | 912 | 564 | [
"DDInter947",
"DDInter7"
] | Interferon beta-1a | Abemaciclib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with . Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. | Moderate | 1 | [
[
[
912,
24,
564
]
],
[
[
912,
24,
868
],
[
868,
24,
564
]
],
[
[
912,
24,
242
],
[
242,
63,
564
]
],
[
[
912,
25,
139
],
[
139,
24,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafeni... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Interferon beta-1a may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Abemaciclib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Abemaciclib
Interferon beta-1a may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Abemaciclib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib |
DB01246 | DB09293 | 820 | 116 | [
"DDInter45",
"DDInter954"
] | Alimemazine | Iodide I-131 | A phenothiazine derivative that is used as an antipruritic. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see or image the isotope. Low levels of beta radiation are also known for causing cancer as this dose is highly mutagenic. For this reason, less toxic iodine isotopes such as I-123 are more frequently used in nuclear imaging, while I-131 is reserved for its tissue destroying effects. Because the thyroid gland naturally takes up iodine from the body, therapeutic methods using radioisotopes can take advantage of this mechanism for localization of drug to the site of malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. | Moderate | 1 | [
[
[
820,
24,
116
]
],
[
[
820,
63,
701
],
[
701,
24,
116
]
],
[
[
820,
25,
1487
],
[
1487,
24,
116
]
],
[
[
820,
24,
516
],
[
516,
2... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenyltoloxamine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine (Compound) resembles Diphenhydramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Iodide I-131 |
DB00363 | DB00816 | 695 | 1,674 | [
"DDInter419",
"DDInter1346"
] | Clozapine | Orciprenaline | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Major | 2 | [
[
[
695,
25,
1674
]
],
[
[
695,
24,
874
],
[
874,
24,
1674
]
],
[
[
695,
63,
1685
],
[
1685,
24,
1674
]
],
[
[
695,
24,
959
],
[
959,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephr... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine (Compound) resembles Trazodone (Compound) and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline |
DB08868 | DB11601 | 1,011 | 1,270 | [
"DDInter737",
"DDInter1889"
] | Fingolimod | Tuberculin purified protein derivative | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
1011,
24,
1270
]
],
[
[
1011,
25,
350
],
[
350,
24,
1270
]
],
[
[
1011,
64,
550
],
[
550,
24,
1270
]
],
[
[
1011,
25,
119
],
[
119,
... | [
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
... | Fingolimod may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00911 | DB04855 | 458 | 540 | [
"DDInter1811",
"DDInter602"
] | Tinidazole | Dronedarone | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone. | Moderate | 1 | [
[
[
458,
24,
540
]
],
[
[
458,
24,
33
],
[
33,
40,
540
]
],
[
[
458,
6,
8374
],
[
8374,
45,
540
]
],
[
[
458,
21,
28883
],
[
28883,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Tinidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Tinidazole (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dronedarone (Compound)
Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dronedarone
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Tinidazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Dronedarone |
DB00685 | DB01030 | 1,299 | 869 | [
"DDInter1887",
"DDInter1835"
] | Trovafloxacin | Topotecan | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Minor | 0 | [
[
[
1299,
23,
869
]
],
[
[
1299,
23,
613
],
[
613,
24,
869
]
],
[
[
1299,
6,
3199
],
[
3199,
57,
869
]
],
[
[
1299,
21,
29276
],
[
29276,
... | [
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Irinotecan"
],
[
... | Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Trovafloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Topotecan (Compound)
Trovafloxacin (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Topotecan (Compound)
Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Trovafloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Caffeine and Caffeine may cause a minor interaction that can limit clinical effects when taken with Topotecan
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan |
DB00999 | DB01261 | 504 | 170 | [
"DDInter883",
"DDInter1679"
] | Hydrochlorothiazide | Sitagliptin | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Moderate | 1 | [
[
[
504,
24,
170
]
],
[
[
504,
21,
28850
],
[
28850,
60,
170
]
],
[
[
504,
24,
52
],
[
52,
62,
170
]
],
[
[
504,
24,
708
],
[
708,
6... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (S... | Hydrochlorothiazide (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Hydrochlorothiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Hydrochlorothiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Hydrochlorothiazide (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Hydrochlorothiazide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sitagliptin |
DB01267 | DB09078 | 519 | 1,228 | [
"DDInter1381",
"DDInter1036"
] | Paliperidone | Lenvatinib | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
519,
24,
1228
]
],
[
[
519,
62,
112
],
[
112,
23,
1228
]
],
[
[
519,
63,
609
],
[
609,
24,
1228
]
],
[
[
519,
24,
1151
],
[
1151,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Paliperidone (Compound) resembles Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Paliperidone may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
Paliperidone may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Lenvatinib
Paliperidone (Compound) resembles Iloperidone (Compound) and Iloperidone may lead to a major life threatening interaction when taken with Lenvatinib
Paliperidone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lenvatinib |
DB01224 | DB06616 | 623 | 594 | [
"DDInter1553",
"DDInter224"
] | Quetiapine | Bosutinib | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
623,
24,
594
]
],
[
[
623,
6,
8374
],
[
8374,
45,
594
]
],
[
[
623,
7,
4786
],
[
4786,
45,
594
]
],
[
[
623,
18,
5833
],
[
5833,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Quetiapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Quetiapine (Compound) upregulates EPHB2 (Gene) and EPHB2 (Gene) is bound by Bosutinib (Compound)
Quetiapine (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Bosutinib (Compound)
Quetiapine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Quetiapine (Compound) resembles Hydroxyzine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib |
DB00637 | DB00889 | 1,557 | 1,133 | [
"DDInter128",
"DDInter840"
] | Astemizole | Granisetron | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
1557,
24,
1133
]
],
[
[
1557,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
1557,
18,
10375
],
[
10375,
57,
1133
]
],
[
[
1557,
23,
112
],
[
11... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Astemizole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Astemizole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Granisetron (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Granisetron
Astemizole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Granisetron
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Astemizole may lead to a major life threatening interaction when taken with Telithromycin and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Astemizole may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron |
DB00420 | DB14568 | 508 | 982 | [
"DDInter1532",
"DDInter1000"
] | Promazine | Ivosidenib | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Major | 2 | [
[
[
508,
25,
982
]
],
[
[
508,
23,
112
],
[
112,
23,
982
]
],
[
[
508,
24,
543
],
[
543,
24,
982
]
],
[
[
508,
25,
11
],
[
11,
25,
... | [
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Promazine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Ivosidenib
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib
Promazine (Compound) resembles Perphenazine (Compound) and Perphenazine may lead to a major life threatening interaction when taken with Ivosidenib
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Promazine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Ivosidenib
Promazine (Compound) resembles Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Ivosidenib
Promazine (Compound) resembles Tamoxifen (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Ivosidenib |
DB06228 | DB11652 | 792 | 1,155 | [
"DDInter1609",
"DDInter1891"
] | Rivaroxaban | Tucatinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Moderate | 1 | [
[
[
792,
24,
1155
]
],
[
[
792,
63,
222
],
[
222,
23,
1155
]
],
[
[
792,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
792,
24,
466
],
[
466,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Rivaroxaban may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Rivaroxaban may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Rivaroxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Tucatinib
Rivaroxaban may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Tucatinib |
DB09054 | DB12887 | 384 | 1,598 | [
"DDInter905",
"DDInter1750"
] | Idelalisib | Tazemetostat | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Major | 2 | [
[
[
384,
25,
1598
]
],
[
[
384,
63,
608
],
[
608,
23,
1598
]
],
[
[
384,
64,
594
],
[
594,
24,
1598
]
],
[
[
384,
25,
985
],
[
985,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Idelalisib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Idelalisib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Idelalisib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Tazemetostat |
DB00570 | DB08820 | 147 | 1,478 | [
"DDInter1936",
"DDInter997"
] | Vinblastine | Ivacaftor | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms. | Moderate | 1 | [
[
[
147,
24,
1478
]
],
[
[
147,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
147,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
147,
23,
307
],
[
307,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Vinblastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Vinblastine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Ivacaftor |
DB00262 | DB10583 | 552 | 949 | [
"DDInter302",
"DDInter415"
] | Carmustine | Clostridium tetani toxoid antigen (formaldehyde inactivated) | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation. | Moderate | 1 | [
[
[
552,
24,
949
]
],
[
[
552,
24,
589
],
[
589,
24,
949
]
],
[
[
552,
25,
1377
],
[
1377,
24,
949
]
],
[
[
552,
63,
58
],
[
58,
24,... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine (Compound) resembles Lomustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) |
DB01064 | DB01234 | 1,148 | 1,220 | [
"DDInter987",
"DDInter513"
] | Isoprenaline | Dexamethasone | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Minor | 0 | [
[
[
1148,
23,
1220
]
],
[
[
1148,
62,
870
],
[
870,
1,
1220
]
],
[
[
1148,
62,
175
],
[
175,
40,
1220
]
],
[
[
1148,
23,
617
],
[
617,
... | [
[
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
... | Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Budesonide and Budesonide (Compound) resembles Dexamethasone (Compound)
Isoprenaline (Compound) treats asthma (Disease) and asthma (Disease) is treated by Dexamethasone (Compound)
Isoprenaline (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dexamethasone (Compound)
Isoprenaline (Compound) binds PIK3R1 (Gene) and PIK3R1 (Gene) is upregulated by Dexamethasone (Compound)
Isoprenaline (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Dexamethasone (Compound)
Isoprenaline (Compound) downregulates UGDH (Gene) and UGDH (Gene) is downregulated by Dexamethasone (Compound)
Isoprenaline (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Dexamethasone (Compound) |
DB00443 | DB01115 | 251 | 336 | [
"DDInter195",
"DDInter1291"
] | Betamethasone | Nifedipine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Moderate | 1 | [
[
[
251,
24,
336
]
],
[
[
251,
63,
1428
],
[
1428,
1,
336
]
],
[
[
251,
24,
1081
],
[
1081,
40,
336
]
],
[
[
251,
24,
409
],
[
409,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine (Compound) resembles Nifedipine (Compound)
Betamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nifedipine (Compound)
Betamethasone (Compound) upregulates ADO (Gene) and ADO (Gene) is upregulated by Nifedipine (Compound)
Betamethasone (Compound) downregulates PHGDH (Gene) and PHGDH (Gene) is upregulated by Nifedipine (Compound)
Betamethasone (Compound) downregulates ATF5 (Gene) and ATF5 (Gene) is downregulated by Nifedipine (Compound)
Betamethasone (Compound) upregulates GLRX (Gene) and GLRX (Gene) is downregulated by Nifedipine (Compound)
Betamethasone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Nifedipine (Compound) |
DB00700 | DB01142 | 312 | 1,264 | [
"DDInter656",
"DDInter593"
] | Eplerenone | Doxepin | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
312,
24,
1264
]
],
[
[
312,
24,
401
],
[
401,
24,
1264
]
],
[
[
312,
6,
8374
],
[
8374,
45,
1264
]
],
[
[
312,
21,
28898
],
[
28898,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eplerenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound)
Eplerenone (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Doxepin (Compound)
Eplerenone may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eplerenone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eplerenone may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eplerenone may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin |
DB00819 | DB08907 | 471 | 1,344 | [
"DDInter15",
"DDInter280"
] | Acetazolamide | Canagliflozin | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
471,
24,
1344
]
],
[
[
471,
24,
549
],
[
549,
1,
1344
]
],
[
[
471,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
471,
21,
29152
],
[
29152,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Acetazolamide (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Canagliflozin (Compound)
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Acetazolamide (Compound) resembles Methazolamide (Compound) and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound)
Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound) |
DB03904 | DB14575 | 1,574 | 733 | [
"DDInter1903",
"DDInter674"
] | Urea | Eslicarbazepine | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1574,
24,
733
]
],
[
[
1574,
63,
222
],
[
222,
24,
733
]
],
[
[
1574,
63,
222
],
[
222,
25,
1264
],
[
1264,
24,
733
]
],
[
[
1574,
... | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"S... | Urea may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine |
DB00019 | DB01030 | 1,257 | 869 | [
"DDInter1405",
"DDInter1835"
] | Pegfilgrastim | Topotecan | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1257,
24,
869
]
],
[
[
1257,
24,
613
],
[
613,
24,
869
]
],
[
[
1257,
24,
310
],
[
310,
63,
869
]
],
[
[
1257,
25,
1064
],
[
1064,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Topotecan
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Topotecan
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan (Compound) treats lung cancer (Disease) and lung cancer (Disease) is treated by Topotecan (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea (Compound) causes Mucosal inflammation (Side Effect) and Mucosal inflammation (Side Effect) is caused by Topotecan (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Topotecan (Compound) |
DB00741 | DB01116 | 167 | 601 | [
"DDInter885",
"DDInter1872"
] | Hydrocortisone | Trimethaphan | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Moderate | 1 | [
[
[
167,
24,
601
]
],
[
[
167,
24,
998
],
[
998,
1,
601
]
],
[
[
167,
25,
593
],
[
593,
63,
601
]
],
[
[
167,
1,
891
],
[
891,
24,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethaphan"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Trimethaphan (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Hydrocortisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Trimethaphan (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Trimethaphan (Compound) |
DB01392 | DB06704 | 425 | 247 | [
"DDInter1954",
"DDInter952"
] | Yohimbine | Iobenguane (I-131) | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
425,
25,
247
]
],
[
[
425,
40,
1340
],
[
1340,
37,
247
]
],
[
[
425,
1,
1245
],
[
1245,
37,
247
]
],
[
[
425,
40,
1340
],
[
1340,
... | [
[
[
"Yohimbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Yohimbine",
"{u} (Compound) resembles {v} (Compound)",
"Deserpidine"
],
[
"Deserpidine",
"{u} may cause a moderate interaction t... | Yohimbine may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) resembles Deserpidine (Compound) and Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Deserpidine may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) resembles Reserpine (Compound) and Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Reserpine may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) resembles Deserpidine (Compound) and Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Tetryzoline may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) resembles Rescinnamine (Compound) and Rescinnamine (Compound) resembles Reserpine (Compound) and Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Reserpine may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) resembles Reserpine (Compound) and Reserpine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Iobenguane (Compound)
Yohimbine (Compound) binds DRD3 (Gene) and DRD3 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) resembles Rescinnamine (Compound) and Rescinnamine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Yohimbine (Compound) resembles Deserpidine (Compound) and Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Pseudoephedrine may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) binds ADRA1D (Gene) and ADRA1D (Gene) is bound by Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane |
DB00465 | DB09268 | 886 | 1,662 | [
"DDInter1010",
"DDInter1464"
] | Ketorolac | Picosulfuric acid | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
886,
24,
1662
]
],
[
[
886,
23,
16
],
[
16,
23,
1662
]
],
[
[
886,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
886,
24,
91
],
[
91,
24... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Ketorolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
... | Ketorolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Ketorolac may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ketorolac (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ketorolac may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Picosulfuric acid
Ketorolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose and Methylcellulose may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Ketorolac may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid |
DB01185 | DB04865 | 155 | 4 | [
"DDInter759",
"DDInter1335"
] | Fluoxymesterone | Omacetaxine mepesuccinate | An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Moderate | 1 | [
[
[
155,
24,
4
]
],
[
[
155,
6,
1899
],
[
1899,
46,
4
]
],
[
[
155,
24,
1296
],
[
1296,
63,
4
]
],
[
[
155,
25,
350
],
[
350,
63,
... | [
[
[
"Fluoxymesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fluoxymesterone",
"{u} (Compound) binds {v} (Gene)",
"NR3C1"
],
[
"NR3C1",
"{u} (Gene) is up... | Fluoxymesterone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fluoxymesterone may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fluoxymesterone (Compound) resembles Testolactone (Compound) and Testolactone may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fluoxymesterone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fluoxymesterone (Compound) resembles Dexamethasone (Compound) and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fluoxymesterone (Compound) resembles Betamethasone (Compound) and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate |
DB06791 | DB11978 | 1,446 | 124 | [
"DDInter1021",
"DDInter822"
] | Lanreotide | Glasdegib | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Moderate | 1 | [
[
[
1446,
24,
124
]
],
[
[
1446,
23,
466
],
[
466,
62,
124
]
],
[
[
1446,
24,
159
],
[
159,
63,
124
]
],
[
[
1446,
24,
1586
],
[
1586,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Lanreotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bepridil and Bepridil may lead to a major life threatening interaction when taken with Glasdegib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Glasdegib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Glasdegib
Lanreotide may lead to a major life threatening interaction when taken with Lonafarnib and Lonafarnib may lead to a major life threatening interaction when taken with Glasdegib
Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib |
DB00209 | DB00373 | 352 | 461 | [
"DDInter1886",
"DDInter1809"
] | Trospium | Timolol | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007. | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Moderate | 1 | [
[
[
352,
24,
461
]
],
[
[
352,
24,
729
],
[
729,
40,
461
]
],
[
[
352,
6,
12523
],
[
12523,
45,
461
]
],
[
[
352,
21,
28769
],
[
28769,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"Pe... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Timolol (Compound)
Trospium (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Timolol (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Trospium (Compound) resembles Clidinium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Levobunolol (Compound) and Levobunolol (Compound) resembles Timolol (Compound)
Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Trospium (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Levobunolol (Compound) and Levobunolol (Compound) resembles Timolol (Compound) |
DB06788 | DB11113 | 1,616 | 657 | [
"DDInter864",
"DDInter307"
] | Histrelin | Castor oil | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. | Moderate | 1 | [
[
[
1616,
24,
657
]
],
[
[
1616,
63,
1079
],
[
1079,
24,
657
]
],
[
[
1616,
24,
927
],
[
927,
63,
657
]
],
[
[
1616,
64,
540
],
[
540,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil |
DB00701 | DB09098 | 1,091 | 98 | [
"DDInter90",
"DDInter1700"
] | Amprenavir | Somatrem | Amprenavir is a protease inhibitor used to treat HIV infection. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
1091,
24,
98
]
],
[
[
1091,
64,
608
],
[
608,
23,
98
]
],
[
[
1091,
63,
168
],
[
168,
23,
98
]
],
[
[
1091,
25,
159
],
[
159,
63... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Amprenavir may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Amprenavir may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Amprenavir may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Amprenavir (Compound) resembles Fosamprenavir (Compound) and Fos
Amprenavir may lead to a major life threatening interaction when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB00497 | DB11817 | 828 | 1,259 | [
"DDInter1366",
"DDInter165"
] | Oxycodone | Baricitinib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022. | Moderate | 1 | [
[
[
828,
24,
1259
]
],
[
[
828,
40,
421
],
[
421,
24,
1259
]
],
[
[
828,
24,
927
],
[
927,
24,
1259
]
],
[
[
828,
64,
475
],
[
475,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may cause a mo... | Oxycodone (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Oxycodone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Oxycodone (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Oxycodone may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Baricitinib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Baricitinib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may lead to a major life threatening interaction when taken with Baricitinib
Oxycodone (Compound) resembles Hydromorphone (Compound) and Hydromorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib |
DB00352 | DB14783 | 482 | 287 | [
"DDInter1814",
"DDInter574"
] | Tioguanine | Diroximel fumarate | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
482,
24,
287
]
],
[
[
482,
63,
1101
],
[
1101,
24,
287
]
],
[
[
482,
24,
384
],
[
384,
24,
287
]
],
[
[
482,
25,
770
],
[
770,
2... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tioguanine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tioguanine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Tioguanine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Tioguanine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB00398 | DB15093 | 79 | 1,654 | [
"DDInter1702",
"DDInter1698"
] | Sorafenib | Somapacitan | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
79,
24,
1654
]
],
[
[
79,
23,
1135
],
[
1135,
24,
1654
]
],
[
[
79,
25,
351
],
[
351,
24,
1654
]
],
[
[
79,
24,
310
],
[
310,
24... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib (Compound) resembles Regorafenib (Compound) and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somapacitan
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB08885 | DB10989 | 363 | 496 | [
"DDInter33",
"DDInter858"
] | Aflibercept | Hepatitis A Vaccine | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain.[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Moderate | 1 | [
[
[
363,
24,
496
]
],
[
[
363,
63,
4
],
[
4,
24,
496
]
],
[
[
363,
24,
738
],
[
738,
63,
496
]
],
[
[
363,
25,
976
],
[
976,
24,
... | [
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine |
DB00078 | DB10897 | 1,172 | 539 | [
"DDInter898",
"DDInter291"
] | Ibritumomab tiuxetan | Capsicum | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1172,
23,
539
]
],
[
[
1172,
25,
885
],
[
885,
23,
539
]
],
[
[
1172,
64,
582
],
[
582,
23,
539
]
],
[
[
1172,
24,
578
],
[
578,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum |
DB00060 | DB00339 | 912 | 1,182 | [
"DDInter947",
"DDInter1547"
] | Interferon beta-1a | Pyrazinamide | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A pyrazine that is used therapeutically as an antitubercular agent. | Moderate | 1 | [
[
[
912,
24,
1182
]
],
[
[
912,
24,
384
],
[
384,
63,
1182
]
],
[
[
912,
63,
305
],
[
305,
24,
1182
]
],
[
[
912,
25,
1510
],
[
1510,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyrazinamide"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisi... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Pyrazinamide
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Pyrazinamide
Interferon beta-1a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Pyrazinamide
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peg
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) binds AOX1 (Gene) and AOX1 (Gene) is bound by Pyrazinamide (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peg
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Pyrazinamide (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Pyrazinamide
Interferon beta-1a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Pyrazinamide |
DB00396 | DB06203 | 989 | 1,002 | [
"DDInter1529",
"DDInter51"
] | Progesterone | Alogliptin | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization, as well as in other formulations to promote and support pregnancy. Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone. Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F389 | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Moderate | 1 | [
[
[
989,
24,
1002
]
],
[
[
989,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
989,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
989,
21,
29321
],
[
2932... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Progesterone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Progesterone (Compound) causes Pancreatitis acute (Side Effect) and Pancreatitis acute (Side Effect) is caused by Alogliptin (Compound)
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Progesterone (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Progesterone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Alogliptin |
DB01229 | DB04908 | 973 | 1,671 | [
"DDInter1377",
"DDInter741"
] | Paclitaxel | Flibanserin | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. | Moderate | 1 | [
[
[
973,
24,
1671
]
],
[
[
973,
63,
168
],
[
168,
23,
1671
]
],
[
[
973,
24,
741
],
[
741,
63,
1671
]
],
[
[
973,
63,
752
],
[
752,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Flibanserin |
DB00275 | DB00741 | 217 | 167 | [
"DDInter1330",
"DDInter885"
] | Olmesartan | Hydrocortisone | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Moderate | 1 | [
[
[
217,
24,
167
]
],
[
[
217,
24,
1220
],
[
1220,
40,
167
]
],
[
[
217,
24,
870
],
[
870,
1,
167
]
],
[
[
217,
21,
28642
],
[
28642,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Olmesartan (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Hydrocortisone (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Olmesartan (Compound) resembles Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Hydrocortisone |
DB00393 | DB14568 | 854 | 982 | [
"DDInter1295",
"DDInter1000"
] | Nimodipine | Ivosidenib | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Moderate | 1 | [
[
[
854,
24,
982
]
],
[
[
854,
63,
1101
],
[
1101,
23,
982
]
],
[
[
854,
1,
1081
],
[
1081,
24,
982
]
],
[
[
854,
24,
770
],
[
770,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Nimodipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Nimodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivosidenib
Nimodipine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Ivosidenib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib |
DB00059 | DB15822 | 1,560 | 69 | [
"DDInter1404",
"DDInter1504"
] | Pegaspargase | Pralsetinib | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment of metastatic RET-fusion positive non-small cell lung cancer. It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines. | Moderate | 1 | [
[
[
1560,
24,
69
]
],
[
[
1560,
63,
1648
],
[
1648,
24,
69
]
],
[
[
1560,
24,
322
],
[
322,
24,
69
]
],
[
[
1560,
24,
609
],
[
609,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Pralsetinib
Pegaspargase may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide (Compound) resembles Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib |
DB00313 | DB01097 | 556 | 1,377 | [
"DDInter1913",
"DDInter1033"
] | Valproic acid | Leflunomide | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
556,
25,
1377
]
],
[
[
556,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
556,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
556,
24,
126
],
[
126,
... | [
[
[
"Valproic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Valproic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"... | Valproic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Valproic acid (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal and Activated charcoal may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may lead to a major life threatening interaction when taken with Leflunomide
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Leflunomide
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Leflunomide
Valproic acid may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Leflunomide |
DB00950 | DB15982 | 1,413 | 1,339 | [
"DDInter732",
"DDInter193"
] | Fexofenadine | Berotralstat | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of [terfenadine] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity. | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022. | Moderate | 1 | [
[
[
1413,
24,
1339
]
],
[
[
1413,
24,
1468
],
[
1468,
24,
1339
]
],
[
[
1413,
24,
868
],
[
868,
25,
1339
]
],
[
[
1413,
23,
609
],
[
609,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Berotralstat
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat |
DB11057 | DB11915 | 720 | 1,293 | [
"DDInter1223",
"DDInter1909"
] | Mineral oil | Valbenazine | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced by solvent extraction, catalytic hydrotreating, or hydrocracking. Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds (PAC) can lead to skin cancer. Mineral oil is a common ingredient in baby lotions, cold creams, ointments and cosmetics to treat and prevent dry, rough, scaly, itchy skin and minor skin irritations. It is also used as a mild laxative for human or veterinary uses. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg. | Moderate | 1 | [
[
[
720,
24,
1293
]
],
[
[
720,
63,
521
],
[
521,
24,
1293
]
],
[
[
720,
24,
927
],
[
927,
24,
1293
]
],
[
[
720,
24,
484
],
[
484,
... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine |
DB08870 | DB09121 | 850 | 1,328 | [
"DDInter228",
"DDInter140"
] | Brentuximab vedotin | Aurothioglucose | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far more effective. | Moderate | 1 | [
[
[
850,
24,
1328
]
],
[
[
850,
63,
367
],
[
367,
24,
1328
]
],
[
[
850,
64,
581
],
[
581,
24,
1328
]
],
[
[
850,
25,
375
],
[
375,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Inte... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Brentuximab vedotin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Brentuximab vedotin may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Aurothioglucose
Brentuximab vedotin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Aurothioglucose
Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Aurothioglucose
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose |
DB01254 | DB04946 | 1,213 | 924 | [
"DDInter484",
"DDInter907"
] | Dasatinib | Iloperidone | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009. | Major | 2 | [
[
[
1213,
25,
924
]
],
[
[
1213,
63,
883
],
[
883,
1,
924
]
],
[
[
1213,
64,
1425
],
[
1425,
25,
924
]
],
[
[
1213,
24,
519
],
[
519,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Iloperidone (Compound)
Dasatinib may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Compound)
Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Iloperidone (Compound)
Dasatinib (Compound) upregulates PIK3C2B (Gene) and PIK3C2B (Gene) is downregulated by Iloperidone (Compound)
Dasatinib (Compound) causes Menstruation irregular (Side Effect) and Menstruation irregular (Side Effect) is caused by Iloperidone (Compound)
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Iloperidone
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone |
DB00191 | DB09100 | 73 | 320 | [
"DDInter1447",
"DDInter1799"
] | Phentermine | Thyroid, porcine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. Currently, patients are more likely to be treated with [levothyroxine]. Thyroid extracts were never FDA approved as their use in the United States predates the FDA. | Moderate | 1 | [
[
[
73,
24,
320
]
],
[
[
73,
24,
127
],
[
127,
24,
320
]
],
[
[
73,
24,
1296
],
[
1296,
63,
320
]
],
[
[
73,
35,
22
],
[
22,
24,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Phentermine (Compound) resembles Ephedrine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Phentermine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene and Isometheptene may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Phentermine (Compound) resembles Ephedrine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine |
DB00491 | DB01069 | 127 | 401 | [
"DDInter1217",
"DDInter1533"
] | Miglitol | Promethazine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
127,
24,
401
]
],
[
[
127,
24,
146
],
[
146,
24,
401
]
],
[
[
127,
24,
820
],
[
820,
63,
401
]
],
[
[
127,
21,
28787
],
[
28787,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Miglitol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Promethazine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Promethazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone may lead to a major life threatening interaction when taken with Promethazine
Miglitol may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Promethazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Promethazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Promethazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00683 | DB12130 | 1,382 | 1,017 | [
"DDInter1212",
"DDInter1094"
] | Midazolam | Lorlatinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019 | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1382,
24,
1017
]
],
[
[
1382,
63,
608
],
[
608,
23,
1017
]
],
[
[
1382,
1,
686
],
[
686,
24,
1017
]
],
[
[
1382,
24,
629
],
[
629,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Midazolam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midazolam may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib |
DB00630 | DB00712 | 1,485 | 1,274 | [
"DDInter42",
"DDInter763"
] | Alendronic acid | Flurbiprofen | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | Moderate | 1 | [
[
[
1485,
24,
1274
]
],
[
[
1485,
7,
19948
],
[
19948,
46,
1274
]
],
[
[
1485,
18,
7623
],
[
7623,
57,
1274
]
],
[
[
1485,
21,
28769
],
[
... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Alendronic acid",
"{u} (Compound) upregulates {v} (Gene)",
"CNPY3"
],
[
"CNPY3",
"{u} (Gene) is upregulat... | Alendronic acid (Compound) upregulates CNPY3 (Gene) and CNPY3 (Gene) is upregulated by Flurbiprofen (Compound)
Alendronic acid (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is downregulated by Flurbiprofen (Compound)
Alendronic acid (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Alendronic acid may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen
Alendronic acid may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen
Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Alendronic acid (Compound) resembles Risedronic acid (Compound) and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen |
DB00563 | DB01324 | 663 | 178 | [
"DDInter1174",
"DDInter1490"
] | Methotrexate | Polythiazide | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
663,
24,
178
]
],
[
[
663,
24,
674
],
[
674,
40,
178
]
],
[
[
663,
63,
1014
],
[
1014,
40,
178
]
],
[
[
663,
21,
28852
],
[
28852,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Polythiazide (Compound)
Methotrexate (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Polythiazide (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Methotrexate may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Methotrexate may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide |
DB09498 | DB11703 | 810 | 405 | [
"DDInter1715",
"DDInter9"
] | Strontium chloride Sr-89 | Acalabrutinib | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Moderate | 1 | [
[
[
810,
24,
405
]
],
[
[
810,
63,
139
],
[
139,
24,
405
]
],
[
[
810,
24,
1619
],
[
1619,
63,
405
]
],
[
[
810,
63,
384
],
[
384,
2... | [
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Acalabrutinib
Strontium chloride Sr-89 may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib |
DB01138 | DB05676 | 804 | 1,513 | [
"DDInter1726",
"DDInter111"
] | Sulfinpyrazone | Apremilast | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation. | Moderate | 1 | [
[
[
804,
24,
1513
]
],
[
[
804,
25,
1421
],
[
1421,
63,
1513
]
],
[
[
804,
62,
1101
],
[
1101,
24,
1513
]
],
[
[
804,
24,
971
],
[
971,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Be... | Sulfinpyrazone may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Apremilast
Sulfinpyrazone may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast |
DB00407 | DB04865 | 202 | 4 | [
"DDInter115",
"DDInter1335"
] | Ardeparin | Omacetaxine mepesuccinate | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Major | 2 | [
[
[
202,
25,
4
]
],
[
[
202,
63,
305
],
[
305,
24,
4
]
],
[
[
202,
24,
738
],
[
738,
63,
4
]
],
[
[
202,
25,
39
],
[
39,
63,
4... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli... | Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ardeparin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ardeparin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ardeparin may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Ardeparin may lead to a major life threatening interaction when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Ardeparin may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Ardeparin (Compound) resembles Fondaparinux (Compound) and Ardeparin may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ardeparin may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate |
DB00372 | DB00690 | 999 | 1,216 | [
"DDInter1793",
"DDInter762"
] | Thiethylperazine | Flurazepam | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
999,
24,
1216
]
],
[
[
999,
24,
1382
],
[
1382,
1,
1216
]
],
[
[
999,
63,
902
],
[
902,
40,
1216
]
],
[
[
999,
63,
1174
],
[
1174,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Flurazepam (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Flurazepam (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Flurazepam (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Flurazepam
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam
Thiethylperazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Flurazepam |
DB00539 | DB01155 | 11 | 872 | [
"DDInter1837",
"DDInter813"
] | Toremifene | Gemifloxacin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | Major | 2 | [
[
[
11,
25,
872
]
],
[
[
11,
25,
739
],
[
739,
1,
872
]
],
[
[
11,
25,
945
],
[
945,
40,
872
]
],
[
[
11,
64,
1176
],
[
1176,
1,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
... | Toremifene may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Toremifene may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
Toremifene may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gemifloxacin (Compound)
Toremifene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Gemifloxacin (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Toremifene may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin
Toremifene may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin |
DB00860 | DB06448 | 891 | 171 | [
"DDInter1513",
"DDInter1087"
] | Prednisolone | Lonafarnib | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] | Moderate | 1 | [
[
[
891,
24,
171
]
],
[
[
891,
1,
1351
],
[
1351,
24,
171
]
],
[
[
891,
24,
473
],
[
473,
24,
171
]
],
[
[
891,
63,
1101
],
[
1101,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a m... | Prednisolone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib |
DB00593 | DB00902 | 1,464 | 104 | [
"DDInter695",
"DDInter1168"
] | Ethosuximide | Methdilazine | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1464,
24,
104
]
],
[
[
1464,
63,
13
],
[
13,
24,
104
]
],
[
[
1464,
24,
820
],
[
820,
1,
104
]
],
[
[
1464,
24,
830
],
[
830,
40... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine (Compound) resembles Methdilazine (Compound)
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Methdilazine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Methdilazine (Compound)
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Thioproperazine (Compound) and Thioproperazine (Compound) resembles Methdilazine (Compound)
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine (Compound) resembles Epinastine (Compound) and Epinastine (Compound) resembles Methdilazine (Compound) |
DB00065 | DB08827 | 581 | 990 | [
"DDInter923",
"DDInter1085"
] | Infliximab | Lomitapide | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
581,
25,
990
]
],
[
[
581,
24,
1409
],
[
1409,
24,
990
]
],
[
[
581,
25,
973
],
[
973,
24,
990
]
],
[
[
581,
25,
1362
],
[
1362,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Infliximab may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Infliximab may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Lomitapide
Infliximab may lead to a major life threatening interaction when taken with Gemtuzumab ozogamicin and Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Lomitapide
Infliximab may lead to a major life threatening interaction when taken with Lomustine and Lomustine may lead to a major life threatening interaction when taken with Lomitapide
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may lead to a major life threatening interaction when taken with Lomitapide
Infliximab may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Lomitapide
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Lomitapide |
DB01067 | DB01211 | 959 | 609 | [
"DDInter826",
"DDInter393"
] | Glipizide | Clarithromycin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
959,
24,
609
]
],
[
[
959,
6,
8374
],
[
8374,
45,
609
]
],
[
[
959,
18,
4360
],
[
4360,
57,
609
]
],
[
[
959,
21,
28662
],
[
28662,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Glipizide (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Clarithromycin (Compound)
Glipizide (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Glipizide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Glipizide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.